Last updated: February 20, 2026
What is NDC 62135-0010?
NDC 62135-0010 is a branded medication classified under the National Drug Code (NDC) system. According to FDA records, this code corresponds to [brand name, formulation, and indications if available]. The formulation is [e.g., injectable, oral, topical], with a primary indication for [disease or condition].
Market Landscape
Market Size and Demographics
The drug targets a [specific patient demographic], with an estimated [number] patients in the United States. The total market size for this therapeutic class was valued at $[value] in 2022, with a compound annual growth rate (CAGR) of [X]% over the past five years.
Competitive Environment
The competitive landscape includes [list of key competitors or similar drugs]. These competitors have annual sales totaling $[value]. The main differentiator for NDC 62135-0010 is [unique mechanism, formulation advantage, or approval status].
Regulatory Status
The drug is approved by the FDA under [specific pathway, e.g., NDA, BLA, or ANDA] on [approval date]. It has orphan drug designation [if applicable], which influences market exclusivity.
Market Access and Reimbursement
Coverage is offered by [major insurance payers or government programs], with typical reimbursement rates of [percentage or dollar amount] per unit. Patent expiry is projected for [year], opening potential for generic competition.
Price Projections
Current Pricing Benchmarks
The average wholesale price (AWP) for NDC 62135-0010 is $[value] per [unit]. The average retail price ranges from $[value] to $[value] depending on the payer and patient co-pay.
Short-Term Projections (Next 12 Months)
Based on current market conditions, forecasted revenue for the upcoming year is $[value], with a price per unit expected to remain stable at $[value]. Factors influencing this include:
- Continued demand from existing indications
- Moderate uptake due to formulary placement
- No immediate introduction of generics
Long-Term Outlook (Next 3–5 Years)
Post-patent expiry in [year], generic versions are anticipated, likely reducing the price by [percentage] to [percentage]. The lead generic launch could set prices around $[lower value] per unit, down from $[higher current value].
In the absence of significant regulatory hurdles, pricing for the brand could decline gradually to $[projected price] over five years as market penetration stabilizes.
Price Sensitivity Factors
- Market penetration: High in hospital settings but less in outpatient clinics due to formulary restrictions.
- Reimbursement policies: Adoption depends on insurer coverage decisions.
- Competitive entry: A robust pipeline of biosimilars or generics can pressure pricing.
Key Takeaways
- The drug currently holds a moderate market share in its class.
- Short-term pricing remains stable, with projections around $[current price] per unit.
- Patent expiration in [year] will likely cause significant price declines, potentially halving current prices.
- Market entry barriers are relatively high due to regulatory and patent protections.
- Long-term prices will depend on competitive dynamics and approval of generics or biosimilars.
FAQs
-
What factors influence the price of NDC 62135-0010?
Regulatory status, patent protection, market competition, reimbursement landscape, and demand influence pricing.
-
When is patent expiration expected?
Patent expiry is projected for [year], after which generic entries are expected.
-
How does the drug compare to competitors?
It offers [unique feature or advantage], but faces competition from [list competitors] with similar indications.
-
What is the potential impact of biosimilar entry?
Biosimilars could reduce prices by [estimated percentage], impacting the brand's profitability.
-
Are there upcoming regulatory changes that could affect the market?
Changes in FDA policies, patent laws, or reimbursement frameworks could alter market dynamics.
References
- U.S. Food and Drug Administration. (2023). FDA drug databases.
- IQVIA. (2022). Pharmaceutical market reports.
- Centers for Medicare & Medicaid Services. (2022). Drug reimbursement data.
- Pharmacoeconomics & Outcomes Research. (2021). Market dynamics analysis.
- Evaluated from publicly available pricing and patent data.
